Status:
UNKNOWN
A Clinical Randomized Controlled Trial of the New Method of Selective Coronary Vein Bypass Graft (SCVBG)
Lead Sponsor:
Beijing Anzhen Hospital
Conditions:
Coronary Atherosclerotic Heart Disease
Eligibility:
All Genders
Up to 70 years
Phase:
NA
Brief Summary
Apply a new operation method of Left Internal Mammary Artery (LIMA)-Greater Saphenous Vein (GSV)-SCVBG to the treatment of patients with diffuse coronary artery disease,through clinical randomized con...
Eligibility Criteria
Inclusion
- Patients with right coronary artery diffuse lesions:Right coronary artery lumen≤1mm，Lesion lengths ≥20mm or multiple segment lesions.
- Patients of coronary artery bypass grafting (CABG) that can't be treated through endarterectomy.
- Patients ≤ 70 years old.
- All enrolled patients must being signed the informed consent.
Exclusion
- Severe heart failure(ejection fraction under 35%) or non coronary atherosclerotic heart disease patients such as combined with severe valvular heart disease.
- Patients with acute myocardial infarction.
- Assistant examinations indicate that the bridge vessels can't be used；The left subclavian artery stenosis and/or LIMA lesions；RIMA lesions；varicosis of both great saphenous vein.
Key Trial Info
Start Date :
November 30 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2018
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT03334110
Start Date
November 30 2017
End Date
September 1 2018
Last Update
November 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing An Zhen Hospital , Capital Medical University
Beijing, Beijing Municipality, China